Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hydrocephalus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: Hydrocephalus. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-018714-73 Sponsor Protocol Number: GE-067-010 CPR Start Date*: 2010-04-26
    Sponsor Name:GE Healthcare Ltd. and its Affiliates
    Full Title: A Principal, Open-Label, Single Center Study to Validate the Detection of Cerebral Cortical Amyloid with Flutemetamol (18F) Injection in Subjects Previously Biopsied
    Medical condition: Patients who have been biopsied during an intracranial procedure due to suspected Normal Pressure Hydrocephalus (NPH)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029773 Normal pressure hydrocephalus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-018715-15 Sponsor Protocol Number: GE-067-011 Start Date*: 2010-05-12
    Sponsor Name:GE Healthcare Ltd. and its Affiliates
    Full Title: A principal, prospective, open-label biopsy study to validate detection of cerebral cortical amyloid with Flutemetamol (18F) Injection in NPH subjects
    Medical condition: Subjects who are scheduled for intracranial pressure measurement or intracranial shunt placement due to suspected Normal Pressure Hydrocephalus (NPH)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029773 Normal pressure hydrocephalus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-004132-22 Sponsor Protocol Number: NPH-01 Start Date*: 2021-01-20
    Sponsor Name:Uppsala University Hospital
    Full Title: Double-blind randomized acetazolamide trial in normal pressure hydrocephalus
    Medical condition: Normal pressure hydrocephalus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10020510 Hydrocephalus acquired LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004664-22 Sponsor Protocol Number: KS1.1 Start Date*: 2020-06-18
    Sponsor Name:Kuopio University Hospital
    Full Title: Stable Isotope Labeling Kinetics in Normal Pressure Hydrocephalus: implications for neurodegeneration
    Medical condition: Idiopathic normal pressure hydrocephalus (iNPH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029773 Normal pressure hydrocephalus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020920-24 Sponsor Protocol Number: Doripenem–CSF Start Date*: 2010-10-20
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Innere Medizin I,Abt. f. Infektionen u.Tropenmedizin
    Full Title: Concentrations of doripenem in the cerebrospinal fluid of neurointensive care patients with extraventricular drainage due to secondary obstructive hydrocephalus
    Medical condition: secondary obstructive hydrocephalus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002337-36 Sponsor Protocol Number: 2007neuro07/R013630/S1 Start Date*: 2008-06-06
    Sponsor Name:Salford Royal NHS Foundation Trust
    Full Title: An open-labelled study of the cerebrospinal fluid pharmacokinetics of intravenous Kineret® in patients with subarachnoid haemorrhage
    Medical condition: This is a pharmacokinetic study in patients who have had a Subarachnoid Haemorrhage and who have had an external ventricular drain inserted for clinical management reasons, must usually for the tre...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042316 Subarachnoid haemorrhage LLT
    9.1 10052947 Ventricular drainage LLT
    9.1 10020508 Hydrocephalus LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003842-18 Sponsor Protocol Number: A301223 Start Date*: 2014-04-24
    Sponsor Name:Erasmus MC
    Full Title: Prevention of renal and bladder damage in children with spina bifida by means of early injections with Botulinum-Toxin-A (Botox): a pilot study.
    Medical condition: Neurogenic bladder function disease in spina bifida patients.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10030685 Open spina bifida LLT
    16.1 100000004850 10041531 Spina bifida without mention of hydrocephalus LLT
    16.1 100000004857 10029280 Neurogenic bladder, not otherwise specified LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-006433-13 Sponsor Protocol Number: TNG-CL008 Start Date*: 2008-06-11
    Sponsor Name:Tengion Inc.
    Full Title: An open-label, multicentre study of augmentation cystoplasty using an autologous Neo-Bladder construct in subjects with spina bifida.
    Medical condition: Neurogenic bladder secondary to spina bifida
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029279 Neurogenic bladder LLT
    9.1 10041524 Spina bifida LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005295-33 Sponsor Protocol Number: S54913 Start Date*: 2013-03-08
    Sponsor Name:UZ Leuven-Department of Urology
    Full Title: Monocentric, open-label, phase III study that compares the efficiency and tolerance between intravesical oxybutynin and oral fesoterodine in children (5-16y) with neurogenic detrusor overactivity.
    Medical condition: children with neurogenic detrusor overactivity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10041524 Spina bifida PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003325-10 Sponsor Protocol Number: 1.01 Start Date*: 2012-08-10
    Sponsor Name:VU University Medical Center
    Full Title: A randomized controlled trail on the effects of periconceptional and prenatal folic acid supplementation on congenital anomalies and preterm birth
    Medical condition: congenital anomalies
    Disease: Version SOC Term Classification Code Term Level
    14.1 10036585 - Pregnancy, puerperium and perinatal conditions 10004953 Birth premature LLT
    14.1 10010331 - Congenital, familial and genetic disorders 10007607 Cardiac septal defects congenital HLT
    14.1 10010331 - Congenital, familial and genetic disorders 10041524 Spina bifida PT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000429-10 Sponsor Protocol Number: 17-030 Start Date*: 2017-10-24
    Sponsor Name:CHU CAEN
    Full Title: FIVHeMA: Intraventricular fibrinolysis versus external ventricular drainage alone in aneurysmal subarachnoid hemorrhage: a randomized controlled trial.
    Medical condition: Patients > 18 years, with aneurysmal SAH complicated by hydrocephalus, requiring insertion of external ventricular drainage
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000013702 10042320 Subarachnoid hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000790-79 Sponsor Protocol Number: 2018-000790-79 Start Date*: 2021-08-09
    Sponsor Name:Academic Medical Centre Amsterdam
    Full Title: IMPROVING OUTCOME IN SUBARACHNOID HEMORRHAGE WITH NADROPARINE
    Medical condition: Patients suffering from an aneurysmal subarachnoid hemorrhage.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005542-42 Sponsor Protocol Number: 2020/11 Start Date*: 2021-03-11
    Sponsor Name:Region Västerbotten
    Full Title: Intrathecal contrast-enhanced MRI for investigation of cerebrospinal fluid transportation
    Medical condition: Cerebrospinal fluid circulation disorder seen in clinically suspected idiopathic normal pressure hydrocephalus
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001673-40 Sponsor Protocol Number: 2015/96 Start Date*: 2015-06-29
    Sponsor Name:Oslo University Hospital
    Full Title: INTRATHECAL CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING
    Medical condition: Cerebrospinal fluid circulation disorder seen in the following clinical disease states: Communicating hydrocephalus, idiopathic intracranial hypertension, idiopathic intracranial hypotension, intra...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000343-26 Sponsor Protocol Number: ULTRA12 Start Date*: 2012-09-06
    Sponsor Name:Academic Medical Center, Neurosurgery
    Full Title: Ultra-early tranexamic acid after subarachnoid hemorrhage. A prospective, randomized, multicenter study.
    Medical condition: subarachnoid hemorrhage
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003087-20 Sponsor Protocol Number: 800_OPBG_2014 Start Date*: 2014-11-12
    Sponsor Name:IRCCS Ospedale Pediatrico Bambino Gesù
    Full Title: Determination of Plasmatic and CSF Levels Of High Doses Of Micafungin in Neonates Suffering from Systemic Candidiasis and/or Candida meningitis.
    Medical condition: Systemic Candidiasis and/or Candida Meningitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10027238 Meningitis fungal NOS LLT
    17.0 100000004852 10027237 Meningeal fungal infections HLT
    17.0 100000004862 10042941 Systemic fungal infection NOS LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006997-27 Sponsor Protocol Number: CRAD001M2301 Start Date*: 2011-06-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC)
    Medical condition: This study will evaluate the antitumor activity of RAD001 versus placebo in patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC).
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) GB (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001542-17 Sponsor Protocol Number: T109/2019Xe-SAH Start Date*: 2020-09-17
    Sponsor Name:Timo Laitio
    Full Title: Effect of xenon on brain injury, neurological outcome and survival in patients after aneurysmal subarachnoid hemorrhage
    Medical condition: Acute rupture of cerebral aneurysm, subarachnoid hemorrhage (SAH), unconsciousness, brain injury.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10008078 Cerebral arterial aneurysm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002584-27 Sponsor Protocol Number: AC-054-301 Start Date*: 2007-11-07
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-caus...
    Medical condition: Indication: Aneurysmal subarachnoid hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042318 Subarachnoid haemorrhage NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) FI (Completed) SE (Completed) DE (Completed) AT (Completed) DK (Completed) ES (Completed) CZ (Completed) IT (Completed) SI (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2018-000241-39 Sponsor Protocol Number: ID-054-304 Start Date*: 2018-08-27
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to...
    Medical condition: Aneurysmal Subarachnoid Hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10039330 Ruptured cerebral aneurysm PT
    21.1 10029205 - Nervous system disorders 10042316 Subarachnoid haemorrhage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) SE (Completed) FR (Completed) CZ (Completed) BE (Completed) DK (Completed) HU (Completed) AT (Completed) PL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 18:33:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA